Echo Therapeutics, Inc, a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, announced a new patent covering its system and methods for transdermal monitoring of analytes, including glucose and other substances.

Echo Therapeutics received notice that its patent application entitled “Transdermal Analyte Monitoring System and Methods for Analyte Detection” has been granted by Japan (Application number 2013-169786) and will expire in 2028. This is a divisional patent, which describes a system utilizing a sensor and a hydrogel with a specific formulation that work together to allow detection of glucose, lactate or other substances. This allowance is significant in that it provides system level protection that matches the design of Echo’s NextGen system.

“This patent, along with the other previously announced Japanese patents, allows us to aggressively pursue business development opportunities that were not previously available in Japan,” said Scott W. Hollander, Echo’s president and CEO. “With the addition of this patent we now have protection in Japan covering our CGM system as opposed to its individual components. We continue to invest in our global IP position in strategically targeted territories for applications of both current and future applications of our technology.”